135 related articles for article (PubMed ID: 6120733)
1. Neuroendocrine tests during treatment with neuroleptic drugs. III. Plasma growth hormone and prolactin responses to apomorphine.
Kolakowska T; Gelder M; Fraser S
Br J Psychiatry; 1981 Nov; 139():408-12. PubMed ID: 6120733
[TBL] [Abstract][Full Text] [Related]
2. Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy.
Ettigi P; Nair NP; Lal S; Cervantes P; Guyda H
J Neurol Neurosurg Psychiatry; 1976 Sep; 39(9):870-6. PubMed ID: 993808
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine tests during treatment with neuroleptic drugs I. Plasma prolactin response to haloperidol challenge.
Kolakowska T; Braddock L; Wiles D; Franklin M; Gelder M
Br J Psychiatry; 1981 Nov; 139():400-4. PubMed ID: 6120731
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine tests during treatment with neuroleptic drugs: I. Plasma prolactin response to chlorpromazine challenge.
Kolakowska T; Fraser S; Franklin M; Knox J
Psychopharmacology (Berl); 1981; 72(3):283-5. PubMed ID: 6111824
[TBL] [Abstract][Full Text] [Related]
5. Effects of apomorphine on blood levels of homovanillic acid, growth hormone and prolactin in medicated schizophrenics and healthy control subjects.
Scheinin M; Syvälahti EK; Hietala J; Huupponen R; Pihlajamäki K; Seppälä OP; Säkö E
Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(4):441-9. PubMed ID: 2866563
[TBL] [Abstract][Full Text] [Related]
6. Drug-induced growth hormone and prolactin responses in schizophrenia research.
Lal S; Nair NP; Iskandar HI; Thavundayil JX; Etienne P; Wood PL; Guyda H
Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):631-7. PubMed ID: 6131495
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine tests during treatment with neuroleptic drugs. II. The TRH test.
Braddock LE; Blake IM
Br J Psychiatry; 1981 Nov; 139():404-7. PubMed ID: 6120732
[TBL] [Abstract][Full Text] [Related]
8. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia.
Meltzer HY; Lee MA; Jayathilake K
Neuropsychopharmacology; 2001 Mar; 24(3):278-90. PubMed ID: 11166518
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone and prolactin response to apomorphine in schizophrenia and the major affective disorders. Relation to duration of illness and depressive symptoms.
Meltzer HY; Kolakowska T; Fang VS; Fogg L; Robertson A; Lewine R; Strahilevitz M; Busch D
Arch Gen Psychiatry; 1984 May; 41(5):512-9. PubMed ID: 6721674
[TBL] [Abstract][Full Text] [Related]
10. Schneider's first-rank symptoms of schizophrenia. An association with increased growth hormone response to apomorphine.
Whalley LJ; Christie JE; Brown S; Arbuthnott GW
Arch Gen Psychiatry; 1984 Nov; 41(11):1040-3. PubMed ID: 6497565
[TBL] [Abstract][Full Text] [Related]
11. Predictors of response to clozapine.
Lieberman JA; Kane JM; Safferman AZ; Pollack S; Howard A; Szymanski S; Masiar SJ; Kronig MH; Cooper T; Novacenko H
J Clin Psychiatry; 1994 Sep; 55 Suppl B():126-8. PubMed ID: 7961556
[TBL] [Abstract][Full Text] [Related]
12. Growth hormone responses to graded doses of apomorphine HCl in schizophrenia.
Cleghorn JM; Brown GM; Brown PJ; Kaplan RD; Mitton J
Biol Psychiatry; 1983 Aug; 18(8):875-85. PubMed ID: 6137249
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine effects of apomorphine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: relations to psychopathology and tardive dyskinesia.
Müller-Spahn F; Ackenheil M; Albus M; May G; Naber D; Welter D; Zander K
Psychopharmacology (Berl); 1984; 84(3):436-40. PubMed ID: 6151210
[TBL] [Abstract][Full Text] [Related]
14. Noradrenergic and dopaminergic interrelation in schizophrenia.
Brambilla F; Marini S; Saito A; Fassone G; Picardi A; Nerozzi D; Pancheri P
Psychiatry Res; 1994 Sep; 53(3):231-42. PubMed ID: 7870845
[TBL] [Abstract][Full Text] [Related]
15. Hormonal effects of apomorphine in schizophrenia.
Ferrier IN; Johnstone EC; Crow TJ
Br J Psychiatry; 1984 Apr; 144():349-57. PubMed ID: 6722395
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine profile of SDZ HDC-912 and OPC-4392, two new atypical antipsychotic drugs, in schizophrenic patients.
Duval F; Mokrani MC; Macher JP; Crocq MA; Castro JO; Bailey P; Lataste X
Psychopharmacology (Berl); 1993; 110(1-2):177-80. PubMed ID: 7870880
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of dopamine agonists and haloperidol on release of prolactin, thyroid stimulating hormone, growth hormone and luteinizing hormone in rats.
Mueller GP; Simpkins J; Meites J; Moore KE
Neuroendocrinology; 1976; 20(2):121-35. PubMed ID: 958594
[TBL] [Abstract][Full Text] [Related]
18. Lack of tolerance to long-term neuroleptic treatment in dopamine tuberoinfundibular system.
Chouinard G; Annable L; Jones BD; Collu R
Acta Psychiatr Scand; 1981 Nov; 64(5):353-62. PubMed ID: 6126066
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal instability of hormone responses in schizophrenia.
Cleghorn JM; Brown GM; Brown PJ; Kaplan RD; Mitton J
Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):545-9. PubMed ID: 6686692
[TBL] [Abstract][Full Text] [Related]
20. Endocrine responses to tryptophan infusion in schizophrenic patients treated with neuroleptics.
Kolakowska T; Cowen PJ; Murdock P
Psychoneuroendocrinology; 1987; 12(3):193-202. PubMed ID: 2887003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
